tetano
Editor, Senior Moderator
mBio
. 2023 Aug 23;e0127323.
doi: 10.1128/mbio.01273-23. Online ahead of print. The current state of research on influenza antiviral drug development: drugs in clinical trial and licensed drugs
Yanbai Li[SUP] #[/SUP][SUP] 1 [/SUP], Shanshan Huo[SUP] #[/SUP][SUP] 1 [/SUP], Zhe Yin[SUP] #[/SUP][SUP] 1 [/SUP], Zuguang Tian[SUP] 2 [/SUP], Fang Huang[SUP] 3 [/SUP], Peng Liu[SUP] 1 [/SUP], Yue Liu[SUP] 4 [/SUP], Fei Yu[SUP] 1 [/SUP]
Affiliations
Influenza viruses (IVs) threaten global human health due to the high morbidity, infection, and mortality rates. Currently, the influenza drugs recommended by the FDA are oseltamivir, zanamivir, peramivir, and baloxavir marboxil. Notably, owing to the high variability of IVs, no drug exists that can effectively treat all types and subtypes of IVs. Moreover, the current trend of drug resistance is likely to continue as the viral genome is constantly mutating. Therefore, there is an urgent need to develop drugs related to the treatment of influenza to deal with the next pandemic. Here, we summarized the cutting-edge research in mechanism of action, inhibitory activity, and clinical efficacy of drugs that have been approved and drugs that are still in clinical trials for influenza treatment. We hope this review will provide up-to-date and comprehensive information on influenza antivirals and generate hypotheses for screens and development of new broad-spectrum influenza drugs in the near future.
Keywords: adverse event; antiviral drugs; clinical drugs; influenza virus; mechanism of action.
. 2023 Aug 23;e0127323.
doi: 10.1128/mbio.01273-23. Online ahead of print. The current state of research on influenza antiviral drug development: drugs in clinical trial and licensed drugs
Yanbai Li[SUP] #[/SUP][SUP] 1 [/SUP], Shanshan Huo[SUP] #[/SUP][SUP] 1 [/SUP], Zhe Yin[SUP] #[/SUP][SUP] 1 [/SUP], Zuguang Tian[SUP] 2 [/SUP], Fang Huang[SUP] 3 [/SUP], Peng Liu[SUP] 1 [/SUP], Yue Liu[SUP] 4 [/SUP], Fei Yu[SUP] 1 [/SUP]
Affiliations
- PMID: 37610204
- DOI: 10.1128/mbio.01273-23
Influenza viruses (IVs) threaten global human health due to the high morbidity, infection, and mortality rates. Currently, the influenza drugs recommended by the FDA are oseltamivir, zanamivir, peramivir, and baloxavir marboxil. Notably, owing to the high variability of IVs, no drug exists that can effectively treat all types and subtypes of IVs. Moreover, the current trend of drug resistance is likely to continue as the viral genome is constantly mutating. Therefore, there is an urgent need to develop drugs related to the treatment of influenza to deal with the next pandemic. Here, we summarized the cutting-edge research in mechanism of action, inhibitory activity, and clinical efficacy of drugs that have been approved and drugs that are still in clinical trials for influenza treatment. We hope this review will provide up-to-date and comprehensive information on influenza antivirals and generate hypotheses for screens and development of new broad-spectrum influenza drugs in the near future.
Keywords: adverse event; antiviral drugs; clinical drugs; influenza virus; mechanism of action.